美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ultra納斯達克生物科

111.73

+1.961.79%

盤後：111.22-0.5147-0.46%19:30 EDT

成交量：5,274

成交額：58.66萬

市值：9,720.92萬

市盈率：- -

高：112.38

開：110.00

低：109.95

收：109.77

52周最高：126.40

52周最低：55.34

股本：87.00萬

流通股本：87.00萬

量比：0.36

換手率：0.61%

股息：0.32

股息率：0.29%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

又爆了！集體飆漲！中東，再傳重磅

安進（AMGN）聯合療法III期臨床達主要終點

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

市場風向標：安進股價遭受重創

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

安進股價或創二十餘年來最大單日跌幅

福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息

TradingKey中文

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌

安進(AMGN)股票9月8日盤中下跌8.33%：真相來了

TradingKey中文

BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華

更正-更新版 1-安進與阿斯利康的藥物組合在晚期研究中幫助肺癌患者延長了生存期

安進股價下跌7%，創下自2025年6月以來最大單日跌幅。

更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標

安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療

Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BIB/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","market":"US","secType":"STK","nameCN":"Ultra納斯達克生物科","latestPrice":111.7347,"timestamp":1789416000000,"preClose":109.7741,"halted":0,"volume":5274,"hourTrading":{"tag":"盘后","latestPrice":111.22,"preClose":111.7347,"latestTime":"19:30 EDT","volume":432,"amount":48013.1882,"timestamp":1789428602354,"change":-0.5147,"changeRate":-0.004606,"amplitude":0.003311},"delay":0,"changeRate":0.017860314955895785,"floatShares":870000,"shares":870000,"eps":0,"marketStatus":"未開盤","change":1.9606,"latestTime":"09-14 16:00:00 EDT","open":110,"high":112.3799,"low":109.95,"amount":586601.7048,"amplitude":0.022135,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":109.7741,"sharesOutstanding":1040000,"nav":109.6885,"aum":95428995,"dividendRate":0.0029,"bidAskSpread":0.002634,"postHourTrading":{"tag":"盘后","latestPrice":111.22,"preClose":111.7347,"latestTime":"19:30 EDT","volume":432,"amount":48013.1882,"timestamp":1789428602354,"change":-0.5147,"changeRate":-0.004606,"amplitude":0.003311},"volumeRatio":0.35626,"impliedVol":0.4834,"impliedVolPercentile":0.752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIB\",,,,,undefined,":{"symbol":"BIB","floatShares":870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.35626,"shares":870000,"dividePrice":0.324,"high":112.3799,"amplitude":0.022135,"preClose":109.7741,"low":109.95,"week52Low":55.34,"pbRate":"--","week52High":126.399,"institutionHeld":0,"latestPrice":111.7347,"eps":0,"divideRate":0.0029,"volume":5274,"delay":0,"ttmEps":0,"open":110,"prevYearClose":79.7794,"prevWeekClose":109.7741,"prevMonthClose":116.5968,"prevQuarterClose":100.74,"fiveDayClose":119.9993,"twentyDayClose":106.8706,"sixtyDayClose":84.9521},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIB\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"BIB","amount":0.00714,"announcedDate":"2026-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-25","defaultRemindTime":1774445400000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-25","currency":"USD","dateTimestamp":1774411200000,"payDate":"2026-03-31"},{"date":"2025-12-24","symbol":"BIB","amount":0.134637,"announcedDate":"2025-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-24","defaultRemindTime":1766586600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-24","currency":"USD","dateTimestamp":1766552400000,"payDate":"2025-12-31"},{"date":"2025-09-24","symbol":"BIB","amount":0.180541,"announcedDate":"2025-09-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-24","defaultRemindTime":1758720600000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-24","currency":"USD","dateTimestamp":1758686400000,"payDate":"2025-09-30"},{"date":"2025-06-25","symbol":"BIB","amount":0.170576,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-07-01"},{"date":"2025-03-26","symbol":"BIB","amount":0.130939,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"Ultra纳斯达克生物科","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-04-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIB\",market:\"US\",,,undefined,":[{"executeDate":"2022-12-22","recordDate":"2022-12-23","paymentDate":"2022-12-30","value":0.019852,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-28","value":0.038393,"currency":"USD"},{"executeDate":"2024-03-20","recordDate":"2024-03-21","paymentDate":"2024-03-27","value":0.040324,"currency":"USD"},{"executeDate":"2024-06-26","recordDate":"2024-06-26","paymentDate":"2024-07-03","value":0.26476,"currency":"USD"},{"executeDate":"2024-09-25","recordDate":"2024-09-25","paymentDate":"2024-10-02","value":0.15285,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PBPH","LU2322448791.USD","IEHS","HELX","GNOM","LU1992135399.USD","TMED","BIB","FBT","XPH","PPH","BK4588","LU2272731865.HKD","RXL","PBE","LU1992135472.HKD","CANC","SYNB","MEDI","BME","BBP","BBH","XBIX","RSPH","IE00B5TLWC47.USD","IDNA","IBB","BIOY","PJP","IBRN","MRNX","LU2272731600.USD","IEIH","FTXH","AZNH","IYH","LFSC","LU2322448957.HKD","BK4585","PSCH","SBIO","MRNY","WDNA","LU2473716301.USD","LU2272731782.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集體飆漲！中東，再傳重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU1983299246.USD","BK4585","LU0868494617.USD","LU2112291526.USD","SG9999001440.SGD","BK4139","PJP","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU1571399168.USD","TBXU","LU0289739699.SGD","LU0320765992.SGD","BK4581","IBBQ","LU0889565916.HKD","LU1057294990.SGD","BK4599","IBB","LU0122379950.USD","IE0002141913.USD","IE0009355771.USD","LU1061106388.HKD","LU2089984988.USD","BK4588","PBE","BK4566","BK4534","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4533","BIB","LU2468319806.SGD","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B2B36J28.USD","AMGN","BBH","LU2242646821.SGD","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4588","BK4534","IE00B4R5TH58.HKD","LU2468319806.SGD","IE00BJT1NW94.SGD","TBXU","LU2242652126.USD","LU0289739699.SGD","LU0320765992.SGD","PBE","BMED","LU2089984988.USD","BK4533","PJP","LU2112291526.USD","IE00B2B36J28.USD","BK4599","MDTX","LU1571399168.USD","AMGN","LU0868494617.USD","LU1057294990.SGD","IE0002141913.USD","PSYK","IE00BFTCPJ56.SGD","LU0122379950.USD","IE0009355771.USD","IBBQ","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4566","IBBJ","LU0889565916.HKD","IBB","LU1023059063.AUD","SG9999001440.SGD","LU1061106388.HKD","BBH","BIB","LU1983299246.USD","BK4585","BK4581","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"us","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1023059063.AUD","LU0868494617.USD","PBE","LU1983299246.USD","IE00B4R5TH58.HKD","LU2112291526.USD","BK4534","IBBQ","LU0289739699.SGD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","AMGN","IE00BJJMRZ35.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU2242646821.SGD","IBB","LU1057294990.SGD","IE0009355771.USD","BIB","IE0002141913.USD","LU2089984988.USD","PJP","BK4581","SG9999001440.SGD","BK4599","BBH","TBXU","BK4566","BK4533","LU2242652126.USD","BK4585","LU2468319806.SGD","LU0058720904.USD","LU1571399168.USD","LU0109394709.USD","LU0122379950.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU1934455194.USD","TMED","LU2087621335.USD","LU1430594728.SGD","LU1778281490.HKD","LU0882574055.USD","LU0965509101.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948897.HKD","TBXU","IE0002270589.USD","IE00B3T34201.USD","LU0861579265.USD","LU0114720955.EUR","BK4139","IBBQ","LU0823416689.USD","LU0965509010.AUD","LU1066051498.USD","LU2089984988.USD","LU2357627491.SGD","LU0889565916.HKD","LU1674673428.USD","LU0859254822.USD","LU0289739699.SGD","LU0965508806.USD","LU1061106388.HKD","LU1674673691.USD","LU1934455277.USD","LU1839511570.USD","LU1023059063.AUD","BK4585","LU1571399168.USD","BK4578","LU1934455863.HKD","IE00BSNM7G36.USD","LU2324357040.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","IE00B19Z3581.USD","BK4532","IE00BKVL7J92.USD","BK4566","LU1037948541.HKD","SG9999015945.SGD","BBH","LU0320765992.SGD","LU2112291526.USD","BK4568","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015986.USD","LU1057294990.SGD","LU1585245621.USD","LU2468319806.SGD","LU0058720904.USD","LU0122379950.USD","MEDI","BK4588","GILD","BMED","BK4550","IBB","SG9999015952.SGD","SG9999015978.USD","ASMB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0965509101.SGD","LU0234570918.USD","LU0823416689.USD","LU2468319806.SGD","ASMB","BK4532","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU0859254822.USD","SG9999015952.SGD","LU1934455194.USD","LU0889565916.HKD","LU1037948541.HKD","LU0965508806.USD","TMED","LU1057294990.SGD","LU0965509283.SGD","LU1934455863.HKD","LU2089984988.USD","SG9999015945.SGD","LU1674673428.USD","LU0114720955.EUR","BIB","LU1778281490.HKD","BK4588","IE00B7SZLL34.SGD","BK4550","LU2087621335.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1674673691.USD","LU1061106388.HKD","BK4566","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1934455277.USD","LU0058720904.USD","LU1571399168.USD","LU0861579265.USD","LU1585245621.USD","IE00B3T34201.USD","IBB","IE00BSNM7G36.USD","MEDI","LU2324357040.USD","BK4578","SG9999015978.USD","IBBQ","LU0965509010.AUD","BBH","TBXU","IE00BKVL7J92.USD","LU0882574055.USD","LU1430594728.SGD","BK4139","LU1023059063.AUD","LU1839511570.USD","BMED","LU0109394709.USD","LU0122379950.USD","IE0002270589.USD","SG9999015986.USD","BK4583","GILD","BK4585","LU1066051498.USD","LU2357627491.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","SG9999015945.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","MEDI","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1934455277.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0965509283.SGD","LU0859254822.USD","LU1571399168.USD","LU1674673428.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU0965509010.AUD","BK4578","LU1057294990.SGD","LU1430594728.SGD","LU1066053197.SGD","GILD","LU1585245621.USD","BIB","BK4550","BK4532","BMED","LU1778281490.HKD","LU0234570918.USD","LU1066051498.USD","LU1023059063.AUD","LU0965508806.USD","BK4568","BK4588","LU1674673691.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0882574055.USD","LU1037948541.HKD","IBBQ","LU0965509101.SGD","LU0058720904.USD","BBH","SG9999015986.USD","ASMB","IBB","IE00B19Z3B42.SGD","IE0002270589.USD","LU0109394709.USD","LU0823416689.USD","BK4139","LU2357627491.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","TMED","LU1037948897.HKD","LU1934455863.HKD","SG9999015952.SGD","BK4583","LU2324357040.USD","BK4566","LU1839511570.USD","LU0861579265.USD","LU1934455194.USD","BK4585","LU2112291526.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU2357627491.SGD","SG9999015978.USD","LU1066051498.USD","LU1934455194.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1674673428.USD","TMED","SG9999015952.SGD","IBB","ASMB","LU1023059063.AUD","LU0320765992.SGD","BK4583","BK4588","LU2087621335.USD","BK4585","IBBQ","LU0965509010.AUD","LU1778281490.HKD","LU0965508806.USD","LU1585245621.USD","BK4578","BK4550","IE00B19Z3581.USD","LU0823416689.USD","LU0882574055.USD","LU2089984988.USD","TBXU","LU0289739699.SGD","LU0861579265.USD","LU0965509283.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU1571399168.USD","LU1674673691.USD","SG9999015986.USD","IE0002270589.USD","LU0109394709.USD","LU1430594728.SGD","BK4568","LU0889565916.HKD","LU1934455277.USD","BBH","BMED","LU2112291526.USD","BIB","LU0058720904.USD","LU0859254822.USD","LU1057294990.SGD","IE00B3T34201.USD","MEDI","LU2324357040.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0965509101.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU2468319806.SGD","LU1066053197.SGD","LU1934455863.HKD","BK4532","GILD","SG9999015945.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安進股價或創二十餘年來最大單日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"hk","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0320765992.SGD","LU2242652126.USD","IE0002141913.USD","BK4599","LU0109394709.USD","PJP","BK4534","BK4566","PBE","AMGN","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","04332","IBB","LU2468319806.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","BIB","BK4533","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU2112291526.USD","LU1023059063.AUD","TBXU","IBBQ","BK4139","LU0289739699.SGD","BK4581","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2089984988.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374214","title":"福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374214","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374214?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:16","pubTimestamp":1788891392,"startTime":"0","endTime":"0","summary":"• Vertex 股价在反弹至接近52周高点后遭遇波动与获利回吐。\n• 对 Crinetics 的收购整合要到2029年才能实现非GAAP增盈。\n• 技术指标显示 MACD 呈中性，RSI 呈中性，威廉指标（Williams %R）呈超卖状态。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156640-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","BK4532","LU1093756168.USD","SG9999013999.USD","BK4585","BK4139","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU0061475181.USD","IE00B894F039.SGD","IE0002141913.USD","BK4533","LU1069344957.HKD","LU0289739699.SGD","LU0234570918.USD","LU1093756325.SGD","LU2362541513.USD","IBBQ","LU0079474960.USD","GNMX","IE00BJT1NW94.SGD","LU1585245621.USD","IE0002270589.USD","SG9999001176.USD","IE0009355771.USD","LU1674673428.USD","SG9999001176.SGD","BIB","LU1778281490.HKD","LU1674673691.USD","LU2362541273.HKD","IE00B19Z9Z06.USD","LU1035775433.USD","LU2417539215.USD","PBE","SGXZ57979304.SGD","LU2089984988.USD","LU1430594728.SGD","BK4588","IDNA","LU0432979614.USD","TBXU","VRTX","LU2362540622.SGD","LU0417517546.SGD","IE00B2B36J28.USD","LU0889565916.HKD","BBH","LU2237438978.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU2324357040.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","IBBQ","BBH","IE00BSNM7G36.USD","LU1839511570.USD","BK4578","LU1674673691.USD","LU1674673428.USD","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU1430594728.SGD","BIB","LU0122379950.USD","BK4568","LU0861579265.USD","LU1023059063.AUD","LU1037948541.HKD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","IE00B19Z3B42.SGD","LU0859254822.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371445","title":"諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371445","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371445?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:41","pubTimestamp":1788885660,"startTime":"0","endTime":"0","summary":"——Royalty Pharma** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”** 计入本交易日涨幅，该股今年以来累计上涨54.7%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4501DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU1057294990.SGD","LU1983299246.USD","IE00BFTCPJ56.SGD","BK4581","BK4007","BIB","LU0868494617.USD","LU1023059063.AUD","SG9999001440.SGD","BK4599","BK4588","IHE","IBBQ","IE00BJJMRZ35.SGD","BBH","LU0058720904.USD","IBB","LU0109394709.USD","IE0002141913.USD","RPRX","LU2242652126.USD","BK4139","PJP","LU0320765992.SGD","BK4533","IE00B4R5TH58.HKD","PBE","IE0009355771.USD","IONS","BK4566","BK4534","AMGN","BK4585","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376637","title":"安進(AMGN)股票9月8日盤中下跌8.33%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376637","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376637?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:16","pubTimestamp":1788876978,"startTime":"0","endTime":"0","summary":"• 诺华 pelacarsen 试验失败，加大了安进竞品 olpasiran 的临床不确定性。\n• 出于对估值的担忧，BMO Capital 将安进的评级从“跑赢大盘”下调至“与大盘持平”。\n• 技术指标显示，安进的 RSI 为 40.256，威廉指标（Williams %R）为 97.857。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156239-market-movers-amgn-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","SG9999001440.SGD","LU2112291526.USD","LU1023059063.AUD","BIB","BBH","IBB","IE00B2B36J28.USD","LU0122379950.USD","BK4534","LU1061106388.HKD","LU2242652126.USD","PJP","BK4533","LU2089984988.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4581","TBXU","LU1057294990.SGD","LU2242646821.SGD","BK4588","LU0868494617.USD","IE00B4R5TH58.HKD","BK4585","LU0109394709.USD","LU1571399168.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4566","AMGN","LU0289739699.SGD","IE0009355771.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4599","IBBQ","LU0889565916.HKD","LU1983299246.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375206","title":"BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375206","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:58","pubTimestamp":1788875887,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Sigma Lithium、Shake Shack、诺华工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透9月8日-周二开盘时，华尔街主要股指涨跌不一，中东地区新一轮冲突推动油价升至7月下旬以来的最高水平，而市场正在等待本周晚些时候","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S45014M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU1548497426.USD","BK4566","IE00B66KJ199.SGD","LU0345769631.USD","BK4131","BE","LU1861559042.SGD","UPGR","BSX","IE00BBT3K403.USD","IONC","IONS","LU0868494617.USD","LU2264538146.SGD","PBE","LU2357125470.USD","BK4504","LU2357305700.SGD","LU0306806265.USD","LU0058720904.USD","LU0128526141.USD","FRNW","LU0138981039.USD","IE00BJT1NW94.SGD","LU1066053197.SGD","LU1093756168.USD","LU1366192091.USD","LU0320765992.SGD","LU2491050071.SGD","LU0070302665.USD","LU0187121727.USD","ICLN","IE000M9KFDE8.USD","BK4556","BK4179","BEG","LU0433182093.SGD","IE00B3T34201.USD","LU1023059063.AUD","SHAK","LU0456855351.SGD","BK4567","SMOG","LU0122379950.USD","BK4209","LU1989764748.USD","LU2491049909.HKD","XES","IE00BLSP4239.USD","EGGY","CTEC","LU1571399168.USD","LU1066051498.USD","LU2543165471.USD","BEC","BK4120","LU0321505439.SGD","LU0823414478.USD","LU1878469433.USD","BK4533","LU0320765489.SGD","PHVS","LU1291159041.SGD","LU1989764664.SGD","LU0476273544.USD","RGTX","LU2242649171.HKD","LU0306807586.USD","BK4121","LU0345769128.USD","LU0823414551.USD","LU0985489474.SGD","LU0225771236.USD","BK4141","LU1720051108.HKD","LU1057294990.SGD","OZEM","BK4588","IE00B7SZL793.SGD","IE0031619046.USD","LU2265009873.SGD","LU2242646821.SGD","WQTM","TBXU","BK4585","LU1989772840.SGD","04332","LU2294711713.HKD","BK4168","IE00B19Z3B42.SGD","LU0234572021.USD","IONQ","LU0957808578.USD","OIH","PJP","LU1894683348.USD","BK4599","CQTM","ROIV","LU1720051017.SGD","SRPT","LU2468319806.SGD","SG9999001176.SGD","LU1983299246.USD","BK4534","LU0077335932.USD","LU0211331839.USD","USNG","BK4102","ALV","IE0009354923.USD","PPH","LU0353189763.USD","CHRW","LU0823416689.USD","RGTU","LU0114720955.EUR","LU0444971666.USD","LU2362540622.SGD","QTUP","LU0011850046.USD","DYN","LU0029874061.USD","LU1791710582.SGD","LU0878866978.SGD","SGML","VTWG","RGTC","IBAT","LU0225283273.USD","LU2087625088.SGD","BK4602","IE00B19Z4B17.USD","BK4578","IOYY","WATS","SEI","LU1153585028.USD","LU2362541513.USD","LU2506952170.USD","BK4581","LU1061106388.HKD","LU2249611893.SGD","LU0170899867.USD","LU0048584097.USD","LU0353189680.USD","BIB","LU0266013472.USD","VCLN","UNFI","LU0882574055.USD","SGXZ57979304.SGD","LU0889565916.HKD","SG9999001440.SGD","LU0289739699.SGD","NTLA","IONL","HYDR","IE00BJJMRZ35.SGD","LU2098885051.SGD","BK4592","IBBQ","LU2491050154.USD","BK4541","SG9999002232.USD","BK4124","IE0009355771.USD","LU2506951958.HKD","BK4597","LU1989772923.USD","LU0238689110.USD","BK4082","LU0985481810.HKD","LU1883839398.USD","LU2506951792.HKD","LU2596442595.SGD","LU0068578508.USD","LU0225284248.USD","MEDX","IE00B4R5TH58.HKD","LU1064131342.USD","LU1791710400.SGD","BEZ","IE00BFTCPJ56.SGD","BK4591","BK4532","LU1804176565.USD","LU2362541273.HKD","RGTZ","LU0950375773.USD","LU1642822529.SGD","LU0432979614.USD","LU2324357040.USD","IE0002270589.USD","SG9999002224.SGD","LU2242652126.USD","BEX","IONX","LU0109394709.USD","LU0528227936.USD","LU2244417387.USD","BBH","IE00BLSP4452.SGD","SG9999003800.SGD","BK4139","LU1894683264.USD","GNOM","BK4568","ILMN","RGTI","BK4170","IE0002141913.USD","RGYY","LU1718418525.SGD","LU1989771016.USD","IBB","SG9999001176.USD","CNRG","LU2089984988.USD","LU0208291251.USD","LU2506951875.HKD","LU1489326972.SGD","ABM","BK4548","SG9999011175.SGD","LU0251132253.USD","LU1815336760.USD","BK4182","GNMX","LU2112291526.USD","LU0823417653.USD","LU1988902786.USD","BK4505","SIMS","LU0823417737.USD","BK4007","BK4535","NVS","LU0321505868.SGD","IE00B2B36J28.USD","IONZ","LU0444973449.USD","LU1093756325.SGD","LU1861558580.USD","SG9999013999.USD","PTH","SRPU","BK4550","IE00B19Z3581.USD","LU0267386448.USD","LU1303367103.USD","ZAP","PFE","IE0034235188.USD","BHVN","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665251375","title":"更正-更新版 1-安進與阿斯利康的藥物組合在晚期研究中幫助肺癌患者延長了生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665251375","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665251375?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:52","pubTimestamp":1788875520,"startTime":"0","endTime":"0","summary":"更新版 1-阿斯利康的联合用药方案在晚期研究中帮助肺癌患者延长了生存期全文补充了有关临床试验和背景的详细信息路透9月8日-阿斯利康AZN.L周二表示，其抗癌药物Imfinzi与安进的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。癌症治疗药物占阿斯利康销售额近一半；2025年，在该公司256.2亿美元的肿瘤产品收入中，Imfinzi贡献了60.6亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T45013T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930490.SGD","PBE","LU0029864427.USD","LU0211326755.USD","LU1196032939.SGD","TBXU","LU0738911758.USD","BBH","LU0889566641.SGD","LU1153585028.USD","LU0158827948.USD","LU0211328371.USD","LU2237443382.USD","LU0969580561.USD","BK4588","AMGN","LU2108987350.USD","LU2468319806.SGD","LU1046234339.USD","IBB","LU2242646821.SGD","LU0997586432.USD","PJP","LU0553294199.USD","LU2089284900.SGD","LU1273509221.SGD","LU0784384876.USD","LU0823416689.USD","LU0171293334.USD","LU2279689827.SGD","BK4533","LU2237443622.USD","BK4585","03165","LU0058720904.USD","IBBQ","AZN.UK","LU0557290698.USD","LU0211327993.USD","LU0792757196.USD","LU0887340254.USD","BIB","LU1267930813.SGD","LU2125909593.SGD","LU0708994859.HKD","IE0009355771.USD","LU1989771016.USD","LU1267930227.SGD","LU0289739699.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安進股價下跌7%，創下自2025年6月以來最大單日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","LU0320765992.SGD","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","PJP","LU1023059063.AUD","BK4581","LU1983299246.USD","IBB","BK4534","IE00BJT1NW94.SGD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732793","title":"更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732793","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873260,"startTime":"0","endTime":"0","summary":"阿斯利康抗癌药物组合在晚期临床试验中达到主要生存目标路透9月8日-阿斯利康（AstraZeneca）AZN.L周二表示，其抗癌药物Imfinzi与安进（Amgen）的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中，显著提高了广泛期小细胞肺癌一线治疗患者的总生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S450114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880407132.USD","LU1084165304.USD","LU1487256676.USD","LU0827474353.SGD","LU0997586515.USD","LU0969580561.USD","LU0882574055.USD","IBBQ","LU0784383803.USD","IBB","LU0058720904.USD","LU0957799991.USD","LU1863844749.USD","LU2433249047.HKD","LU1023059063.AUD","BBH","BIB","PBE","PJP","LU0109394709.USD","LU0661504455.SGD","AMGN","LU1003076772.USD","LU1923622614.USD","LU1046234339.USD","LU0077335932.USD","LU1061106388.HKD","LU0289739699.SGD","LU2355687059.USD","03165","LU1829250122.USD","LU2242652126.USD","LU0203347892.USD","BK4139","LU2279689827.SGD","BK4599","LU0122379950.USD","LU0545039389.USD","LU0868494617.USD","TBXU","LU2091194634.USD","LU0920783379.SGD","IE0034235188.USD","LU0526926950.USD","LU1481599808.USD","LU0889566641.SGD","LU1170363599.USD","LU2237443465.HKD","AZN.UK","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115495471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1057294990.SGD","BK4585","BK4581","LU0868494617.USD","BK4599","LU1983299246.USD","LU0058720904.USD","IBB","IE00B4R5TH58.HKD","LU1571399168.USD","SG9999001440.SGD","LU2089984988.USD","PJP","IBBQ","LU0289739699.SGD","BK4588","BBH","BK4534","LU1023059063.AUD","IE0009355771.USD","LU0889565916.HKD","LU2242652126.USD","IE00BJJMRZ35.SGD","BIB","PBE","AMGN","IE00BJT1NW94.SGD","LU0320765992.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","LU0109394709.USD","IE0002141913.USD","TBXU","LU2112291526.USD","BK4533","IE00BFTCPJ56.SGD","BK4139","BK4566","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109517247?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","BK4534","IE0002141913.USD","BK4566","LU0122379950.USD","LU2468319806.SGD","BBH","LU2112291526.USD","BK4533","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","BK4599","IE00BJT1NW94.SGD","BK4585","LU0058720904.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0868494617.USD","IBB","PBE","LU0889565916.HKD","BIB","LU1057294990.SGD","BK4588","LU1061106388.HKD","BK4139","LU1983299246.USD","IBBQ","PJP","LU2242652126.USD","LU0109394709.USD","LU1023059063.AUD","LU2089984988.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU0289739699.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":142,"code":"91000000","status":"200"}]}}